Sacituzumab+RAI/Dxd

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameSacituzumab+RAI/Dxd

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payload > MAAA-1181a payload

Mechanisms of ActionAnti-Trop-2Ribosome inhibitorsDNA topoisomerase I inhibitors

TargetsTumor-associated calcium signal transducer 2DNA topoisomerase IRibosome

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHexagon Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesHexagon Bio Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A